FDA Grants Breakthrough Status to Aidoc's AI Radiology System

FDA recognizes AI system addressing radiology workflow challenges

The Food and Drug Administration has designated Aidoc's First Read as a breakthrough device, recognizing its potential to address mounting interpretation delays in hospital radiology departments. The AI system generates preliminary report text from chest radiograph analysis, aiming to reduce the time clinicians spend on initial documentation.

According to details first reported by Medical Device Network, the designation comes as health systems face increasing imaging volumes and growing concerns about report turnaround times. The breakthrough device pathway is reserved for technologies that could substantially improve diagnosis or treatment of serious conditions while addressing unmet clinical needs.

How the technology works

First Read builds on the technical foundation of Aidoc's previously FDA-cleared abdominal CT triage application. The system produces high-quality preliminary drafts of radiology reports, allowing radiologists to dedicate more time to clinical judgment rather than initial documentation tasks.

The underlying platform, aiOS, integrates into existing imaging and electronic medical record workflows. Aidoc's clinical AI infrastructure currently operates in nearly 2,000 hospitals globally, including major health systems like Sutter Health, Wellspan Health, and Mercy. The company reports analyzing more than 120 million patient cases to date.

Why it matters

Radiology departments face a structural challenge: imaging demand continues rising while the radiologist workforce remains constrained. Preliminary report generation represents a different approach than diagnostic AI—rather than flagging abnormalities, it tackles the documentation burden that consumes significant clinician time. If validated in real-world deployment, this could meaningfully change how radiology workflows operate, particularly in high-volume settings where interpretation backlogs delay patient care decisions.

Aidoc's expanding regulatory portfolio

This marks the second breakthrough device designation for Aidoc in less than a year. The company's CARE Triage system received the same status in September 2025. The dual designations signal FDA recognition of the company's approach to clinical AI deployment.

Aidoc CEO and co-founder Elad Walach characterized the technology as addressing tools that "were never designed for today's scale of imaging demand." The company recently closed a $150 million Series E financing round and continues expanding its platform deployment.

In September 2024, Aidoc secured CE marking for four additional AI algorithms on its aiOS platform, enabling deployment across European healthcare providers.

These details were originally reported by Medical Device Network, a GlobalData publication.